2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1034

Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis
Abstract Number: 1035

Risk of Hospitalization Among RA Patients with Multiple Autoimmune Co-Morbidities Differs By DMARD Treatment
Abstract Number: 1036

Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Abstract Number: 1037

Biosimilar Knowledge Among US Rheumatologists – a Survey
Abstract Number: 1038

Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis
Abstract Number: 1039

Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Abstract Number: 1040

Perceptions of US Community Rheumatologists on Biosimilars
Abstract Number: 1041

Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Abstract Number: 1042

Remote Management of Osteoporosis Screening and Treatment in US Veterans Using a Bone Health Team: A Cost-Effectiveness Analysis
Abstract Number: 1043

Comparison of the Costs for Hyaluronic Acid and Total Knee Arthroplasty in the Treatment of OA for the Blue Cross/Blue Shield Patient Population
Abstract Number: 1044

Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Abstract Number: 1045

The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis
Abstract Number: 1046

Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Abstract Number: 1047

Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Abstract Number: 1048

Efficacy of Educating Visiting Pharmacists Regarding Drug Administration for Patients with Rheumatoid Arthritis Who Poorly Adhere to Treatment Regimens

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].